8:11 AM
 | 
Dec 03, 2018
 |  BC Extra  |  Clinical News

RedHill planning NDA for H. pylori antibiotic following second Phase III readout

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) plans to submit an NDA to FDA next half for Talicia (RHB-105) as first-line treatment of Helicobacter pylori infection regardless of ulcer status after reporting that the antibiotic met the primary endpoint in the Phase III ERADICATE Hp2 trial in the...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >